EZH2 mediated the expression suppression of MHC I and MHC II, while EZH2 inhibition increased tumor immunogenicity, the expression of MHC I and MHC II, and the function of antigen presentation, thereby promoting CD8+ T cell-mediated tumor cell killing and increasing the inhibitory effect of PD-1 or PD-L1 inhibitors on tumor growth (Fig. 5) [90–93]. Here, CD8A is linked to neoplasm.